Trial Profile
Immunogenicity and Safety of the Trivalent Influenza Vaccine (Split-Virion, Inactivated), Northern Hemisphere 2013-2014 Formulation (Intradermal Route)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Apr 2014
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi Pasteur
- 19 Apr 2014 New trial record